The firm also said its partner BioNTech won't exercise its option rights for the CD19- and CD22-directed CAR T-cell therapy candidate AUTO1/22.

An intravenous form of the gene therapy is already approved and sold as Zolgensma in the US for patients less than 2 years of age.

The firm's LLM-based platform abstracted complex information from medical charts with up to 100 percent accuracy in a pilot study of breast cancer patients.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

Precision Medicine Online's 2024 survey shows biomarker test expansion but low clinical trial enrollment and long wait times ...

The firm's stock price dropped 27 percent on Tuesday following the news that the young man died from acute liver failure after getting Elevidys.

In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.

NEW YORK – AstraZeneca on Monday said it signed an agreement to acquire EsoBiotec, a company that is developing in vivo engineered cell therapies, for up to $1 billion. EsoBiotec's Engineered NanoBody ...

NEW YORK – European regulators have cleared Anocca to begin a Phase I/II umbrella trial of its lead targeted T-cell receptor (TCR) therapy ANOC-001 and other pipeline candidates in certain advanced ...

NEW YORK – InformedDNA on Wednesday said it has acquired Coriell Life Sciences, a pharmacogenomics and clinical-decision support company. St. Petersburg, Florida-based InformedDNA, which provides ...

By correcting for ancestral bias in publicly available datasets, PhyloFrame produces better outcomes predictions for ...

NEW YORK – The US Food and Drug Administration has granted Precision BioSciences permission to begin a Phase I trial of its in vivo gene-editing therapeutic candidate for chronic hepatitis B virus ...